The primary objective of this study is to describe the socio-demographic, clinical pathological, quality of life and treatment characteristics of patients diagnosed with CC in Brazil.
The primary objective of this study is to describe the socio-demographic, clinical pathological, quality of life and treatment characteristics of patients diagnosed with cervix cancer (CC) in Brazil. Other specific objectives are: * To describe socio-demographic characteristics: age at diagnosis, education, family income, race, occupation, personal health habits - e.g.oral contraceptive use ever/never and duration; smoking never/ever/current/duration , ever drinking), sexual history, insurance coverage (private, public), institution (private, public, philanthropic), obstetric history, comorbidities, performance status, human papillomavirus vaccination or not * To describe the screening for CC: access, type, frequency and results. * To describe clinical pathological characteristics of CC: histology (adeno x squamous x adenosquamous x neuroendocrine x other) , International Federation of Gynecology and Obstetrics (FIGO) stage, pathological stage, exams for staging, date of diagnosis, site of metastasis. * To describe treatment characteristics of CC: date of surgery, type of surgery; date and duration of radiotherapy, type of radiotherapy; date, type and lines of systemic therapy (chemotherapy, monoclonal antibodies), * To describe treatment safety (grade 3-4 AEs, death due to treatment toxicity, discontinuation due to AE). In addition adverse events of special interest will be described (details on Safety section). * To describe the outcomes: follow-up exams and date of visits, persistent disease, recurrence, progression times in metastatic disease, complications (e.g. hydronephrosis/nephrostomy/ GI perforations and both GI \& genitourinary fistulae.), death due CC and death from any cause.
Study Type
OBSERVATIONAL
Enrollment
638
The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.
Fundação Centro de Controle do Câncer do Estado do Amazonas
Manaus, Amazonas, Brazil
CRIO
Fortaleza, Ceará, Brazil
Clínica AMO
Salvador, Estado de Bahia, Brazil
Characterization of cervix cancer in the Brazilian female population
Time frame: 3 years
Socio-demographic characteristics of the female population diagnosed with CC
Time frame: Month 0 (beginning of the study)
Description of the method used to diagnose the brazillian female patients with cervix cancer
Screening tests (Papanicolaou test) or symptoms presented by patients
Time frame: Month 0
The clinical and pathological characteristics of cervix cancer in brazilian female patients
Time frame: Month 0
Type of treatment assessed in patients with CC
Radiotherapy, Chemotherapy and/or Surgery
Time frame: Month 0, 3, 6,12, 24 and 36
Number of patients with disease survival
Time frame: Month 3, 6, 12, 24 and 36
Number of patients with progression survival
Time frame: Month 3, 6, 12, 24 and 36
Number of patients with overall survival
Time frame: Month 3, 6, 12, 24 and 36
Number of patients with disease overall survival
Time frame: Month 3, 6, 12, 24 and 36
Type and description of the indicated treatment after the diagnosis of cervix cancer in brazilian female patients
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
HU Walter Cantídeo
Ceará, Fortaleza, Brazil
Hospital Alderona Bello
São Luís, Maranhão, Brazil
UFMG
Belo Horizonte, Minas Gerais, Brazil
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil
IMIP
Recife, Pernambuco, Brazil
Hospital São Vicente de Paulo
Passo Fundo, Rio Grande do Sul, Brazil
CPO - Hsl/Pucrs
Porto Alegre, Rio Grande do Sul, Brazil
...and 6 more locations
Time frame: Month 0, 3, 6,12, 24 and 36
Duration of treatment after the diagnosis of cervix cancer
Time frame: Month 0, 3, 6,12, 24 and 36
Description of adverse effects of the cervix cancer treatment
Time frame: Month 0, 3, 6,12, 24 and 36
Number of adverse effects of the cervix cancer treatment
Time frame: Month 0, 3, 6,12, 24 and 36
Type of clinical outcomes of the patients with cervix cancer in Brazil
Time frame: Month 0, 3, 6,12, 24 and 36